EMA Recommends Two Blood Cancer Drugs For Approval

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended granting marketing authorisations for ibrutinib and idelalisib...

ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.